Gene One Life Science revises VGXI buyback option extension terms, sets USD 4 million deposit due Oct. 30

• Gene One Life Science corrected a subsidiary disclosure on VGXI’s extension of a buyback option tied to its Conroe plant deed-in-lieu deal.
• Board decision date revised to Oct. 9, 2026 from Sept. 23, 2026, reflecting execution of an amended extension agreement.
• Buyback price kept at USD 39.9 million, with a USD 4 million deposit due Oct. 30, 2026.
• Balance of USD 35.9 million due Dec. 15, 2026, matching the extended option maturity date.
• Contract now terminates automatically if the deposit is not paid by the deadline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012800717), on October 12, 2026, and is solely responsible for the information contained therein.